Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
BETHESDA, Md., Nov. 10, 2017 -- India Globalization Capital, Inc. (NYSE American:IGC) announced that it received a letter on November 9, 2017 from NYSE Regulation stating that it is in compliance with the NYSE American LLC continued listing standards set forth in Section 704 of the NYSE American Company Guide. Specifically, IGC held an annual meeting on November 8, 2017. As is the case for all listed issuers, the Company’s continued listing eligibility will continue to be assessed on an ongoing basis.
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.
For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC's Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.
Contact:
Claudia Grimaldi
301-983-0998
